Efficacy and safety of tumor acidic microenvironment-targeted hepatic arterial chemoembolization for treating hepatocellular carcinoma

WU Yi; SONG Yu-sheng; ZHOU Tong-gang; YU Chun-lin; ZENG Dao-lin; LI Xing-hai; ZHONG Bao-liang

doi:10.13820/j.cnki.gdyx.20241750

Abstract：Objective To evaluate the efficacy and safety of tumor acidic microenvironment-targeted hepatic ar-terial chemoembolization(TILA-TACE)for treating hepatocellular carcinoma(HCC).Methods A retrospective anal-ysis was performed on clinical data from HCC patients who received TILA-TACE at Ganzhou People's Hospital from Sep-tember 2016 to September 2020.The short-term efficacy,target lesion diameter changes,treatment-related adverse effects,and overall survival time were assessed.Results A total of 67 patients were included,with a mean age of(51.2±11.7)years,including 60 males.Tumor staging based on BCLC was as follows:Stage 0(4 patients),Stage A(15 pa-tients),Stage B(11 patients),and Stage C(37 patients).CNLC staging was:Ⅰa(12 patients),Ⅰb(7 patients),Ⅱa(4 patients),Ⅱb(7 patients),Ⅲa(22 patients),and Ⅲb(15 patients).Based on mRECIST criteria,8 patients(11.9％)achieved complete response(CR)and 28 patients(41.8％)achieved partial response(PR)after the initial TILA-TACE.The objective response rate(ORR)was 53.7％(95％CI:41.5％-66.0％),and the disease control rate(DCR)was 82.1％(95％CI:72.7％-91.5％).As of April 1,2024,the median follow-up time was 10 months.The median survival time was 12.1 months(95％CI:6.4-17.8 months).The 1-year,2-year,3-year,and 5-year cumulative survival rates were 51.3％,29.5％,20.2％,and 7.1％,respectively.Major adverse reactions included abdominal pain(79.1％),elevated alanine aminotransferase(35.8％),and elevated serum bilirubin(32.8％).Conclusion TILA-TACE demonstrates local anti-tumor efficacy for liver tumors with controllable safety.However,the precise efficacy requires further evaluation through multicenter,large-scale,prospective randomized con-trolled studies.